Non-Human Primate (NHP) models with spontaneously developed diabetes mirror every aspects of the human disease, including:
- Glucose intolerance
- Reduced glucose disposition
- Insulin resistance (Euglycemic &hyperinsulinemic clamp)
- Insulin dependency at late stage
- High-fat-induced dyslipidemia
Therefore, our in vivo pharmacology expertise in diabetic NHPs provide the highest level of confidence for the go/no go decision making in the drug discovery process. Such studies can not only provide deep biological insights into the pharmacological mechanisms of a drug, but also help to identify biomarkers important to clinical trial design (i.e. patient stratification and study rationale).